← Leaderboards
Pamela Tinmoi Wong
University Of Michigan At Ann Arbor
$1,927,527
Attributed
$3,855,054
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2022–25$2M$1.5M$1M$500K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$3,855,054 · 3
By mechanism
R01$2,917,054 · 1
R21$938,000 · 2
Top collaborators
- Michael Schotsaert8 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Mark M Painter$442,028
- Jolanta Grembecka$12,187,788
- Tomasz Cierpicki$10,333,927
- Katherine Ann Gallagher$14,068,065
- Andrew P Lieberman$22,338,719
Others in their field
Other Rising Stars on “Influenza”
- Anice Lowen · Emory University$10,657,790
- Philip Felgner · University Of California-Irvine$10,234,165
- Gregory Sorenson · University Of Maryland Baltimore County$9,161,697
- Lisa Wagar · University Of California-Irvine$8,240,577
- Vel Murugan · Arizona State University-Tempe Campus$7,910,715
- Li Liang · University Of California-Irvine$7,511,446
Research focus
InfluenzaImmuneRouteVirusImmunityInfluenzavirusLungResponseVaccinationVaccinesImmune ResponseAgonistAntibodiesAdjuvantInfectionIntramuscularMucous MembraneNanoemulsionAnimalsCovid-19 VaccineDoseInnate Immune ResponseAutomobile DrivingCoronavirus
Grant awards (8)
Combined adjuvant approaches for enhancement of SARS-CoV-2 vaccine efficacy$721,321
R01 · FY2025 · AI · contact PI
Impact of mucosal adjuvanted vaccines on virus transmission in preclinical animal models for SARS-CoV-2 and influenza virus infection$208,000
R21 · FY2025 · AI
Combined adjuvant approaches for enhancement of SARS-CoV-2 vaccine efficacy$725,845
R01 · FY2024 · AI · contact PI
Impact of mucosal adjuvanted vaccines on virus transmission in preclinical animal models for SARS-CoV-2 and influenza virus infection$264,250
R21 · FY2024 · AI
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity$204,750
R21 · FY2024 · AI
Combined adjuvant approaches for enhancement of SARS-CoV-2 vaccine efficacy$725,288
R01 · FY2023 · AI · contact PI
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity$261,000
R21 · FY2023 · AI
Combined adjuvant approaches for enhancement of SARS-CoV-2 vaccine efficacy$744,600
R01 · FY2022 · AI · contact PI